Averitas Pharma
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.qutenza.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Averitas Pharma
Averitas Pharma, Inc. specializes in QUTENZA, a capsaicin-based treatment designed for managing diabetic nerve pain of the feet and post-shingles nerve pain. The company aims to provide sustained pain relief for patients suffering from these conditions. Their services include connecting patients with QUTENZA specialists and offering savings on treatment. The company primarily targets residents of the United States.Explore more
Popular SearchesAveritas Pharma IncQutenzaQutenza( capsaicin) 8% patchSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Averitas Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Averitas Pharma launches new products
Averitas Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Averitas Pharma
Check if Averitas Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Averitas Pharma recently announced quarterly report
Funding: Get notified immidiatlly once Averitas Pharma has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Averitas Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Averitas Pharma is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Averitas Pharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to Averitas Pharma
Compare insights from companies similar to Averitas Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Averitas Pharma
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Averitas Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Averitas Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Averitas Pharma.
Averitas Pharma Tech Stack
A closer look at the technologies used by Averitas Pharma
Averitas Pharma News & Media
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect
AACHEN, Germany and VICTORIA, Australia, Feb. 24, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered...Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures1, thus affecting more than 3 million people with surgical procedures per year in the U.S....First patient enrolled in a Phase III study with QUTENZA® in post-surgical neuropathic pain
AACHEN, Germany and MORRISTOWN, N.J., Aug. 10, 2021 /PRNewswire/ -- Grünenthal announced today that its U.S. subsidiary, Averitas Pharma Inc., enrolled the first patient in the randomised, double-blind trial AV001. The Phase III study investigates the efficacy, safety, and tolerability of...Grünenthal and Averitas Pharma announce initiation of Phase III study with QUTENZA® to prepare label extension in the US for the treatment of post-surgical neuropathic pain
AACHEN, Germany and MORRISTOWN, N.J., March 30, 2021 /PRNewswire/ -- Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc. will conduct a Phase III trial to study the efficacy, safety and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Averitas Pharma
Sign Up For FreeTo access detailed company insights
Averitas Pharma, Inc. specializes in QUTENZA, a capsaicin-based treatment designed for managing diabetic nerve pain of the feet and post-shingles nerve pain. The company aims to provide sustained pain relief for patients suffering from these conditions. Their services include connecting patients with QUTENZA specialists and offering savings on trea... Read More
